• Photocure ASA licensee Asieris struck an exclusive deal with Theramex to develop and commercialize Cevira across Europe, Australia, New Zealand, Turkey.
• Asieris kept rights for the rest of the world.
• Cevira is a photodynamic drug-device product for non-surgical treatment of cervical precancerous lesions, including HSIL.
• China’s NMPA cleared Cevira in March 2026 for non-invasive treatment of cervical precancerous lesions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Photocure ASA published the original content used to generate this news brief on October 07, 2026, and is solely responsible for the information contained therein.